Interrelationship of canonical and non-canonical Wnt signalling pathways in chronic metabolic diseases

Diabetes and Vascular Disease Research

Volumn 15, Issue 1, 2018, Pages 3-13

  Ackers, Ian ^a,b   Malgor, Ramiro ^a  

^a OHIO UNIVERSITY   (United States)

^b OHIO UNIVERSITY   (United States)

Author keywords

cardiovascular disease; diabetes; kidney disease; metabolic disease; non alcoholic fatty liver disease; Wnt signalling

Indexed keywords

CYCLOOXYGENASE 2; LIPID; MAMMALIAN TARGET OF RAPAMYCIN; VASCULAR CELL ADHESION MOLECULE 1; WNT PROTEIN;

CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CHRONIC DISEASE; CHRONIC KIDNEY FAILURE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENDOTHELIUM CELL; FIBROSIS; HUMAN; INFLAMMATION; LIFESTYLE; LIPID STORAGE; MACROPHAGE; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PROTEIN DOMAIN; PROTEIN FUNCTION; REVIEW; VASCULAR SMOOTH MUSCLE CELL; WNT SIGNALING; ANIMAL; ENERGY METABOLISM; HOMEOSTASIS; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; CHRONIC DISEASE; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; METABOLIC DISEASES; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 85038594854     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164117738442     Document Type: Review

References (100)

1. Nusse R, Varmus HE., Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982; 31: 99–109.
2. Nüsslein-Volhard C, Wieschaus E., Mutations affecting segment number and polarity in Drosophila. Nature 1980; 287: 795–801.
3. Nusse R, Brown A, Papkoff J. A new nomenclature for int-1 and related genes: the Wnt gene family. Cell 1991; 64: 231.
4. Logan CY, Nusse R., The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004; 20: 781–810.
5. Nugent R., Chronic diseases in developing countries. Ann N Y Acad Sci 2008; 1136: 70–79.
6. Ricanati EH, Golubić M, Yang D. Mitigating preventable chronic disease: progress report of the Cleveland clinic’s lifestyle 180 program. Nutr Metab 2011; 8: 83.
7. Hwang I, Seo E, Ha H., Wnt/β-catenin signaling: a novel target for therapeutic intervention of fibrotic kidney disease. Arch Pharm Res 2010; 32: 1653–1662.
8. Zhou L, Li Y, Hao S. Multiple genes of the renin-angiotensin system are novel targets of Wnt/β-catenin signaling. J Am Soc Nephrol 2015; 26: 107–120.
9. Reuter S, Beckert H, Taube C., Take the Wnt out of the inflammatory sails: modulatory effects of Wnt in airway diseases. Lab Invest 2016; 96: 177–185.
10. Wang S, Song K, Srivastava R. Nonalcoholic fatty liver disease induced by noncanonical Wnt and its rescue by Wnt3a. FASEB J 2015; 29: 3436–3445.
11. Christodoulides C, Lagathu C, Sethi JK. Adipogenesis and WNT signalling. Trends Endocrinol Metab 2009; 20: 16–24.
12. Van Bezooijen RL, Svensson JP, Eefting D. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 2007; 22: 19–28.
13. Bretón-Romero R, Feng B, Holbrook M. Endothelial dysfunction in human diabetes is mediated by Wnt5a-JNK signaling. Arterioscler Thromb Vasc Biol 2016; 36: 561–569.
14. Sen M, Chamorro M, Reifert J. Blockade of Wnt-5A/frizzled 5 signaling inhibits rheumatoid synoviocyte activation. Arthritis Rheum 2001; 44: 772–781.
15. Catalán V, Gómez-Ambrosi J, Rodríguez A. Activation of noncanonical Wnt signaling through Wnt5a in visceral adipose tissue of obese subjects is related to inflammation. J Clin Endocrinol Metab 2014; 99: E1407–E1417.
16. Bhatt PM, Lewis CJ, House DL. Increased Wnt5a mRNA expression in advanced atherosclerotic lesions, and oxidized LDL treated human monocyte-derived macrophages. Open Circ Vasc J 2012; 5: 1–7.
17. Gordon MD, Nusse R., Wnt Signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006; 281: 22429–22433.
18. Clevers H, Nusse R., Wnt/β-catenin signaling and disease. Cell 2012; 149: 1192–1205.
19. Stamos JL, Weis WI., The β-catenin destruction complex. Cold Spring Harb Perspect Biol 2013; 5: a007898.
20. Kikuchi A, Yamamoto H, Sato A. Wnt5a: its signalling, functions and implication in diseases. Acta Physiol 2012; 204: 17–33.
21. Yamamoto S, Nishimura O, Misaki K. Cthrc1 selectively activates the planar cell polarity pathway of Wnt signaling by stabilizing the Wnt-receptor complex. Dev Cell 2008; 15: 23–36.
22. Park HW, Kim YC, Yu B. Alternative Wnt signaling activates YAP/TAZ. Cell 2015; 162: 780–794.
23. Topol L, Jiang X, Choi H. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent β-catenin degradation. J Cell Biol 2003; 162: 899–908.
24. Van Amerongen R, Nusse R. Towards an integrated view of Wnt signaling in development. Development 2009; 136: 3205–3214.
25. Corbett L, Mann J, Mann DA., Non-canonical Wnt predominates in activated rat hepatic stellate cells, influencing HSC survival and paracrine stimulation of Kupffer cells. PLoS ONE 2015; 10: e0142794.
26. Anagnostou SH, Shepherd PR., Glucose induces an autocrine activation of the Wnt/β-catenin pathway in macrophage cell lines. Biochem J 2008; 416: 211–218.
27. Kurayoshi M, Yamamoto H, Izumi S. Post-translational palmitoylation and glycosylation of Wnt-5a are necessary for its signalling. Biochem J 2007; 402: 515–523.
28. Panáková D, Sprong H, Marois E. Lipoprotein particles are required for Hedgehog and wingless signalling. Nature 2005; 435: 58–65.
29. Neumann S, Coudreuse DYM, Van Der Westhuyzen DR. Mammalian Wnt3a is released on lipoprotein particles. Traffic 2009; 10: 334–343.
30. Fuster JJ, Zuriaga MA, Ngo DT-M. Noncanonical Wnt signaling promotes obesity-induced adipose tissue inflammation and metabolic dysfunction independent of adipose tissue expansion. Diabetes 2015; 64: 1235–1248.
31. Carstensen M, Wiza C, Rohrig K. Effect of Sfrp5 on cytokine release and insulin action in primary human adipocytes and skeletal muscle cells. PLoS ONE 2014; 9: e0085906.
32. Lin H, Angeli M, Chung KJ. sFRP2 activates Wnt/β-catenin signaling in cardiac fibroblasts: differential roles in cell growth, energy metabolism and extracellular matrix remodeling. Am J Physiol: Cell Physiol 2016; 311: C710–C719.
33. Ouchi N, Higuchi A, Ohashi K. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science 2010; 329: 454–457.
34. Katoh M, Katoh M., STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer (review). Int J Mol Med 2007; 19: 273–278.
35. Katz DL, Meller S., Can we say what diet is best for health? Annu Rev Public Health 2014; 35: 83–103.
36. Bhatt PM, Malgor R., Wnt5a: a player in the pathogenesis of atherosclerosis and other inflammatory disorders. Atherosclerosis 2014; 237: 155–162.
37. Gerdes S, Laudes M, Neumann K. Wnt5a: a potential factor linking psoriasis to metabolic complications. Exp Dermatol 2014; 23: 439–440.
38. Ståhle M., Psoriasis: in between the skin and the fat. Exp Dermatol 2015; 24: 181–182.
39. Blumenthal A, Ehlers S, Lauber J. The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. Blood 2006; 108: 965–973.
40. Katoh. Transcriptional mechanisms of WNT5A based on NF-κB, Hedgehog, TGFβ, and notch signaling cascades. Int J Mol Med 2009; 23: 763–769.
41. Wise DR, DeBerardinis RJ, Mancuso A. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci 2008; 105: 18782–18787.
42. Kim N-G, Xu C, Gumbiner BM., Identification of targets of the Wnt pathway destruction complex in addition to β-catenin. Proc Natl Acad Sci 2009; 106: 5165–5170.
43. Castilho RM, Squarize CH, Chodosh LA. mTOR mediates Wnt-induced epidermal stem cell exhaustion and aging. Cell Stem Cell 2009; 5: 279–289.
44. Zoncu R, Efeyan A, Sabatini DM., mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21–35.
45. Schwartz DR, Wu R, Kardia SLR. Novel candidate targets of β-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res 2003; 63: 2913–2922.
46. Sethi JK, Vidal-Puig A., Wnt signalling and the control of cellular metabolism. Biochem J 2010; 427: 1–17.
47. Farb MG, Bigornia S, Mott M. Reduced adipose tissue inflammation represents an intermediate cardiometabolic phenotype in obesity. J Am Coll Cardiol 2011; 58: 232–237.
48. Farb MG, Karki S, Park S-Y. WNT5A-JNK regulation of vascular insulin resistance in human obesity. Vasc Med 2016; 21: 489–496.
49. Malgor R, Bhatt PM, Connolly BA. Wnt5a, TLR2 and TLR4 are elevated in advanced human atherosclerotic lesions. Inflamm Res 2014; 63: 277–285.
50. Cheng W-L, Yang Y, Zhang X-J. Dickkopf-3 ablation attenuates the development of atherosclerosis in ApoE-deficient mice. J Am Heart Assoc 2017; 6: e004690.
51. Hurt RT, Kulisek C, Buchanan LA. The obesity epidemic: challenges, health initiatives, and implications for gastroenterologists. Gastroenterol Hepatol 2010; 6: 780–792.
52. Farmer SR., Regulation of PPARγ activity during adipogenesis. Int J Obes 2005; 29: S13–S16.
53. van Tienen FHJ, Laeremans H, van der, Kallen CJH. Wnt5b stimulates adipogenesis by activating PPARγ, and inhibiting the β-catenin dependent Wnt signaling pathway together with Wnt5a. Biochem Biophys Res Commun 2009; 387: 207–211.
54. Sánchez-Solana B, Laborda J, Baladrón V., Mouse resistin modulates adipogenesis and glucose uptake in 3T3-L1 preadipocytes through the ROR1 receptor. Mol Endocrinol 2012; 26: 110–127.
55. Ross SE, Hemati N, Longo KA. Inhibition of adipogenesis by Wnt signaling. Science 2000; 289: 950–953.
56. Lu H, Li X, Mu P. Dickkopf-1 promotes the differentiation and adipocytokines secretion via canonical Wnt signaling pathway in primary cultured human preadipocytes. Obes Res Clin Pract 2016; 10: 454–464.
57. Bilkovski R, Schulte DM, Oberhauser F. Role of Wnt-5a in the determination of human mesenchymal stem cells into preadipocytes. J Biol Chem 2010; 285: 6170–6178.
58. Bilkovski R, Schulte DM, Oberhauser F. Adipose tissue macrophages inhibit adipogenesis of mesenchymal precursor cells via wnt-5a in humans. Int J Obes 2011; 35: 1450–1454.
59. Ruan H, Lodish HF., Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-α. Cytokine Growth Factor Rev 2003; 14: 447–455.
60. Li X, Shan J, Chang W. Chemical and genetic evidence for the involvement of Wnt antagonist Dickkopf2 in regulation of glucose metabolism. Proc Natl Acad Sci U S A 2012; 109: 11402–11407.
61. Samuel VT, Liu Z-X, Qu X. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004; 279: 32345–32353.
62. Taitano AA, Markow M, Finan JE. Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. J Gastrointest Surg 2015; 19: 429–437.
63. Tian F, Zhang YJ, Li Y. Celecoxib ameliorates non-alcoholic steatohepatitis in type 2 diabetic rats via suppression of the non-canonical Wnt signaling pathway expression. PLoS ONE 2014; 9: e83819.
64. Go G, Srivastava R, Hernandez-Ono A. The combined hyperlipidemia caused by impaired Wnt-LRP6 signaling is reversed by Wnt3a rescue. Cell Metab 2014; 19: 209–220.
65. Behari J, Yeh T-H, Krauland L. Liver-specific β-catenin knockout mice exhibit defective bile acid and cholesterol homeostasis and increased susceptibility to diet-induced steatohepatitis. Am J Pathol 2010; 176: 744–753.
66. Yin X, Yi H, Wang L. RSPOs facilitated HSC activation and promoted hepatic fibrogenesis. Oncotarget 2016; 7: 63767–63778.
67. Beljaars L, Daliri S, Dijkhuizen C. WNT-5A regulates TGF-β-related activities in liver fibrosis. Am J Physiol: Gastrointest Liver Physiol 2017; 312: G219–G227.
68. GBD 2013 Mortality and Causes of Death Collaborators. Global regional national age–sex specific all-cause cause-specific mortality for 240 and causes of death, 1990–2013: a systematic analysis for the global burden of disease study 2013. Lancet 2015; 385: 117–171.
69. Iglesias DM, Hueber P-A, Chu L. Canonical WNT signaling during kidney development. Am J Physiol: Ren Physiol 2007; 293: F494–F500.
70. He W, Dai C, Li Y. Wnt/β-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 2009; 20: 765–776.
71. Yeh T-H, Krauland L, Singh V. Liver-specific β-catenin knockout mice have bile canalicular abnormalities, bile secretory defect, and intrahepatic cholestasis. Hepatology 2010; 52: 1410–1419.
72. Dai C, Stolz DB, Kiss LP. Wnt/β-Catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol 2009; 20: 1997–2008.
73. Hewitson TD, Ono T, Becker GJ., Small animal models of kidney disease: a review. Methods Mol Biol Clifton NJ 2009; 466: 41–57.
74. Huang L, Scarpellini A, Funck M. Development of a chronic kidney disease model in C57BL/6 mice with relevance to human pathology. Nephron Extra 2013; 3: 12–29.
75. Surendran K, Schiavi S, Hruska KA., Wnt-dependent β-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the progression of renal fibrosis. J Am Soc Nephrol 2005; 16: 2373–2384.
76. Zaman MA, Oparil S, Calhoun DA., Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov 2002; 1: 621–636.
77. Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease. Circulation 2007; 116: 85–97.
78. Mozaffarian D, Benjamin EJ, Go AS. Heart disease and stroke statistics-2016 update. Circulation 2015; 133: e38–e360.
79. Imakita M, Yutani C, Strong JP. Second nation-wide study of atherosclerosis in infants, children and young adults in Japan. Atherosclerosis 2001; 155: 487–497.
80. Christman MA, Goetz DJ, Dickerson E. Wnt5a is expressed in murine and human atherosclerotic lesions. Am J Physiol: Heart Circ Physiol 2008; 294: H2864–H2870.
81. Palevski D, Levin Kotler L-P, Kain D. Loss of macrophage Wnt secretion improves remodeling and function after myocardial infarction in mice. J Am Heart Assoc 2017; 6: e004387.
82. Naghavi M, Libby P, Falk E. From vulnerable plaque to vulnerable patient a call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108: 1664–1672.
83. Libby P, Ridker PM, Maseri A., Inflammation and atherosclerosis. Circulation 2002; 105: 1135–1143.
84. Herr F, Horndasch M, Howe D. Human placenta-derived Wnt-5a induces the expression of ICAM-1 and VCAM-1 in CD133+CD34+-hematopoietic progenitor cells. Reprod Biol 2014; 14: 262–275.
85. Malhotra S, Kincade PW., Canonical Wnt pathway signaling suppresses VCAM-1 expression by marrow stromal and hematopoietic cells. Exp Hematol 2009; 37: 19–30.
86. Eto M, Kouroedov A, Cosentino F. Glycogen synthase kinase-3 mediates endothelial cell activation by tumor necrosis factor-α. Circulation 2005; 112: 1316–1322.
87. Derlindati E, Dei Cas A, Montanini B. Transcriptomic analysis of human polarized macrophages: more than one role of alternative activation? PLoS ONE 2015; 10: e0119751.
88. Naskar D, Maiti G, Chakraborty A. Wnt5a-Rac1-NF-κB homeostatic circuitry sustains innate immune functions in macrophages. J Immunol 2014; 192: 4386–4397.
89. Pereira CP, Bachli EB, Schoedon G., The wnt pathway: a macrophage effector molecule that triggers inflammation. Curr Atheroscler Rep 2009; 11: 236–242.
90. Pereira C, Schaer DJ, Bachli EB. Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10. Arterioscler Thromb Vasc Biol 2008; 28: 504–510.
91. Yang L, Chu Y, Wang Y. siRNA-mediated silencing of Wnt5a regulates inflammatory responses in atherosclerosis through the MAPK/NF-κB pathways. Int J Mol Med 2014; 34: 1147–1152.
92. Hansson GK, Libby P, Tabas I., Inflammation and plaque vulnerability. J Intern Med 2015; 278: 483–493.
93. Kirton JP, Crofts NJ, George SJ. Wnt/β-catenin signaling stimulates chondrogenic and inhibits adipogenic differentiation of pericytes. Circ Res 2007; 101: 581–589.
94. Williams H, Mill CAE, Monk BA. Wnt2 and WISP-1/CCN4 induce intimal thickening via promotion of smooth muscle cell migration. Arterioscler Thromb Vasc Biol 2016; 36: 1417–1424.
95. Tsaousi A, Williams H, Lyon CA. Wnt4/β-catenin signaling induces VSMC proliferation and is associated with intimal thickening. Circ Res 2011; 108: 427–436.
96. Hua J, Xu Y, He Y. Wnt4/β-catenin signaling pathway modulates balloon-injured carotid artery restenosis via disheveled-1. Int J Clin Exp Pathol 2014; 7: 8421.
97. Kumawat K, Menzen MH, Bos IST. Noncanonical WNT-5A signaling regulates TGF-β-induced extracellular matrix production by airway smooth muscle cells. FASEB J 2013; 27: 1631–1643.
98. Wu X, Wang J, Jiang H. Wnt3a activates β1-integrin and regulates migration and adhesion of vascular smooth muscle cells. Mol Med Rep 2014; 9: 1159–1164.
99. Mill C, Monk BA, Williams H. Wnt5a-induced Wnt1-inducible secreted protein-1 suppresses vascular smooth muscle cell apoptosis induced by oxidative stress. Arterioscler Thromb Vasc Biol 2014; 34: 2449–2456.
100. Pandey S, Chandravati. Wnt signaling cascade in restenosis: a potential therapeutic target of public health relevance in a North American cohort of Nebraska State. Mol Biol Rep 2014; 41: 4549–4554.